Figure A1.

Dark (■) and light-induced (□) loss of cellular viability after mTHPC-mediated PDT or treatment with Pt(II) complexes cisplatin (CDDP), carboplatin (CDBCA) and oxaliplatin (1-OHP) as assessed by the MTT viability assay in SISO cells as a representative sample. Cells were treated with mTHPC for 24 h in concentrations ranging from 0.001–5.0 µM and kept in the dark (dark toxicity) or illuminated with light between λ = 640–660 nm and a light fluence of 1.8 J/cm², applied at a fluence rate of 3.0 mW/cm². MTT assay was carried out 24 h post illumination and the absorbance of the reduced formazan was measured at λ = 570 nm. The IC₅₀ values for the Pt(II) complexes were detected 48 h after treatment without illumination of the cells. Concentrations varied for CDDP (0.01–50.0 µM), CBDCA (0.1–250 µM; 0.001–5.0 mM for A-427) and 1-OHP (0.1–100 µM). The percentage of cell viability was calculated by dividing the absorbance for the treated group by the absorbance in the solvent dark control. IC₅₀ values were calculated using Prism 6. Results presented as means ± SD from at least three independent experiments.